ArticleBlood advances2021
Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer.
Article in Blood advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Is Circulating Vitamin D Status Associated with the Risk of Venous Thromboembolism? A Meta-Analysis of Observational Studies.Nutrients · 2023Pooled it
- MOF promotes venous thromboembolism in lung cancer by activating the YBX1-MALT1-NF-κB-PAI-1 axis, possibly through histone crotonylation.The Journal of biological chemistry · 2026Article
- Microfluidic Platforms for Modeling Cancer-Associated Thrombosis: Current Status and Future Directions.Research and practice in thrombosis and haemostasis · 2026Review
- A stromal PAI1-tPA axis orchestrates immunosuppression in pancreatic cancer.Science advances · 2026Article
- Plasmin Generation Kinetics Reveal a Hyperfibrinolytic Phenotype in Patients with Pancreatic Ductal Adenocarcinoma.TH open : companion journal to thrombosis and haemostasis · 2026Article
- Clinical features and prognosis of patients with malignant tumors complicated by cerebral infarction.American journal of cancer research · 2026Article
- Clot formation, structure, and fibrinolysis of plasma from pancreatic cancer patients.Journal of thrombosis and thrombolysis · 2025Article
- Hexokinase 2-mediated histone H3K18la promotes PAI-1-dependent thrombosis in acute myeloid leukemia via tumor-endothelial crosstalk.Nature communications · 2025Article
- Unmasking the genetic double agents of hyperglycemia: Mendelian randomization in endotheli-hell espionage.Atherosclerosis · 2025Article
- Review
- Radiotherapy-the not-so-insignificant contributor to cancer-associated venous thrombosis.Research and practice in thrombosis and haemostasis · 2025Review
- The multifaceted roles of extracellular vesicles in osteonecrosis of the femoral head.Journal of orthopaedic translation · 2025Review
- Do human adipose stem cell-derived artificial insulin-producing cells develop tumorigenic characteristics throughout differentiation?Molecular biology reports · 2025Article
- Article
- Review
- Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancer.EBioMedicine · 2024Article
- Circulating IgG Fragments for Gastric Cancer and Esophageal Cancer.Diagnostics (Basel, Switzerland) · 2024Article
- Mucin 1 and venous thrombosis in tumor-bearing mice and patients with cancer.Thrombosis research · 2024Article
- The pathogenesis of cancer-associated thrombosis.International journal of hematology · 2024Review
- EML4-ALK fusion protein in Lung cancer cells enhances venous thrombogenicity through the pERK1/2-AP-1-tissue factor axis.Journal of thrombosis and thrombolysis · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 3 countries.
Funding
Abstract
Pancreatic cancer patients have a high risk of venous thromboembolism (VTE). Plasminogen activator inhibitor 1 (PAI-1) inhibits plasminogen activators and increases the risk of thrombosis. PAI-1 is expressed by pancreatic tumors and human pancreatic cell lines. However, to date, there are no studies analyzing the association of active PAI-1 and VTE in pancreatic cancer patients. We investigated the association of active PAI-1 in plasma and VTE in pancreatic cancer patients. In addition, we determined if the presence of human pancreatic tumors expressing PAI-1 impairs venous thrombus resolution in mice. Plasma levels of active PAI-1 in patients with pancreatic cancer and mice bearing human tumors were determined by enzyme-linked immunosorbent assay. We measured PAI-1 expression in 5 different human pancreatic cancer cell lines and found that PANC-1 cells expressed the highest level. PANC-1 tumors were grown in nude mice. Venous thrombosis was induced by complete ligation of the inferior vena cava (IVC). Levels of active PAI-1 were independently associated with increased risk of VTE in patients with pancreatic cancer (subdistribution hazard ratio per doubling of levels: 1.39 [95% confidence interval, 1.09-1.78], P = .007). Mice bearing PANC-1 tumors had increased levels of both active human and active mouse PAI-1 and decreased levels of plasmin activity. Importantly, mice bearing PANC-1 tumors exhibited impaired venous thrombus resolution 8 days after IVC stasis compared with nontumor controls. Our results suggest that PAI-1 contributes to VTE in pancreatic cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.